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Abstract
Background: The development of targeted therapies has undoubtedly broadened therapeutic options for patients
with colorectal cancer (CRC). The use of bevacizumab to reduce angiogenesis has been associated with improved
clinical outcomes. However, an urgent need for prognostic/predictive biomarkers for anti-angiogenic therapies still
exists.
Methods: Clinical data of 105 CRC patients treated with bevacizumab in conjunction with chemotherapy were
analyzed. The expression of vascular endothelial growth factor (VEGF) receptors, NOTCH1 receptor and its ligand
DLL4 were determined by immunohistochemistry. Tumor samples were arranged on a tissue microarray. The
association between protein expression and clinicopathological characteristics and outcomes was determined.
Results: Bevacizumab was administered as a first-line of treatment in 70.5 % of our cases. The median progression-free
survival (PFS) was 10.2 months. The median overall survival (OS) of the total cohort was 24.4 months. Bevacizumab, as
the first-line of treatment, and the presence of liver metastasis were independently associated with objective response
rate. Membrane VEGFR1 and VEGFR3 expressions were associated with the presence of lung metastasis; interestingly,
VEGFR3 was associated with less liver metastasis. NOTCH1 expression was associated with lymph node metastasis.
There was a trend toward association between improved PFS and lower NOTCH1 expression (p = 0.06). Improved OS
was significantly associated with lower NOTCH1 expression (p = 0.01). In a multivariate analysis, ECOG (Eastern
Cooperative Oncology Group) performance status, liver metastasis, histological grade, and NOTCH1 expression
were independently associated with OS.
Conclusion: Our findings illustrated the expression profile of angiogenesis-related proteins and their association
with clinicopathological characteristics and outcomes. NOTCH1 expression is a detrimental prognostic factor in
metastatic CRC patients treated with chemotherapy plus bevacizumab.
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Background
Colorectal cancer (CRC) is the fourth most common
cause of death worldwide, accounting for 694,000 deaths
in 2012. CRC incidence is higher in men than in women,
being the third most common cancer in men and the
second in women [1]. Almost 50 % of patients will develop
metastases and ~25 % already have metastasis at diagnosis
[2]. Although CRC incidence and mortality rates vary
markedly around the world, CRC is mainly a disease of
developed Western countries. For 2015, it has been esti-
mated that the United States will have 132,700 new cases
of CRC and 49,700 related deaths [3]. In Brazil, 32,600
new cases of colorectal cancer were expected in 2014
(http://www.inca.gov.br/estimativa/2014/).
Angiogenesis induction is pivotal to tumor growth and
metastases. From a molecular perspective, angiogenesis is
triggered by hypoxia, cytokines, oncogenes activating mu-
tations, growth factors and hormones that directly or
indirectly promote the production and release of an
array of proteins genetically and functionally related
to VEGFA (vascular endothelial growth factor A).
Subsequently, these proteins bind to and activate spe-
cific membrane tyrosine-kinase receptors (VRGFR1,
VEGFR2 and VEGFR3) [4].
Similarly, a family of membrane bound receptors related
to the protein NOTCH (NOTCH1, NOTCH2, NOTCH3
and NOTCH4) interact with membrane bound ligands
(JAGGED-1 or JAG1, JAG2, delta-like-1 or DLL1, DLL3
and DLL4) and act to regulate cell proliferation, differenti-
ation and apoptosis, as well as angiogenesis and tumor cell
migration [5, 6]. Some data suggest that VEGFR2 activa-
tion by VEGFA upregulates DLL4 in tip cells. DDL4 in
turn binds to and activates NOTCH1 on stalk cells, redu-
cing VEGFR2 expression and subsequently increasing
VEGFR1, thus constituting a negative feedback for the
activity of VEGFA [7].
In the last several years, the development of targeted
therapies has provided therapeutic options for patients
with metastatic CRC in addition to improved clinical
outcomes. The median overall survival (OS) has increased
by > 12 months since the introduction of therapies using
biological compounds and doublet/triplet chemother-
apy regimens [8]. Bevacizumab (Avastin: Genentech,
San Francisco, CA, USA), a monoclonal antibody, is a
potent inhibitor of vascular endothelial growth factor
(VEGF), and has been shown to reduce angiogenesis [9].
The efficacy and safety of bevacizumab have been demon-
strated as both a first and second-line treatment [10–12].
In combination with chemotherapy, bevacizumab has
been shown to improve the overall response rate (RR),
median progression-free survival (PFS) and median OS
[13]. The majority of previously untreated metastatic
CRC patients are now treated with bevacizumab in com-
bination with oxaliplatin and fluorouracil (FOLFOX) [14].
Furthermore, recent data have shown some clinical benefit
in maintaining VEGF inhibition with bevacizumab beyond
disease progression [15].
Although significant improvements in outcome rates
have been reported with various anti-VEGF agents, a sub-
stantial number of patients do not obtain a pronounced
benefit, which is most likely due to resistance mechanisms
[16]. DLL4-induced Notch signaling, one of the mecha-
nisms reported to mediate tumor resistance related to
anti-VEGF therapy, activates multiple parallel pathways
and induces the formation of large distorted vessels [7].
The Notch signaling pathway has emerged as an attractive
target for angiogenesis-based cancer therapies [17]. How-
ever, despite the increasing role of various antiangiogenic
drugs in personalized metastatic CRC care, no biomarkers
have been identified capable of predicting response to
antiangiogenic therapy. Several markers have been tested
in preclinical models but failed as predictors of response
in human trials [18]. Thus, there is an urgent need for
prognostic/predictive biomarkers for anti-VEGF therapies.
In this retrospective study, clinical features and out-
comes in a cohort of 105 CRC patients who received
bevacizumab-containing regimens were reviewed and pre-
sented. The expression of VEGF receptors, NOTCH1
receptor and its ligand DLL4 in CRC tissues as well as the
evaluation of their relationships with clinicopathological
characteristics and outcomes were determined retrospect-
ively. Importantly, the patient population was relatively
homogeneous due to consistent eligibility criteria, treat-
ment guidelines, and evaluation parameters.
Methods
Patients and study design
The medical data from CRC metastatic patients treated
with a combination of bevacizumab and chemotherapy
were retrospectively analyzed. All data from May 2006
to November 2009 were obtained from chemotherapy
registries from A.C. Camargo Cancer Center - Fundação
Antônio Prudente. A total of 151 patients were found.
Paraffin blocks were available for 117 patients, but in 11
of them the data or material were not suitable for analysis,
therefore, a total of 105 patients were eligible for further
study (Fig. 1). The study was approved by the Ethics Com-
mittee of A.C. Camargo Cancer Center - Fundação
Antônio Prudente (number 1134/08). The need of an in-
formed consent was waived by Ethics Committee.
Demographic and clinical data were collected and in-
cluded relevant medical history, disease stage, tumor
pathology at the initial diagnosis, details of chemother-
apy regimens used with bevacizumab, data concerning
the primary surgery, and metastasectomy. Tumors were
staged according to the 7th edition of the TNM classifi-
cation of malignant tumors [19]. Data for the response
criteria and survival outcomes were based on the chart
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review. Response criteria were evaluated according to
the Response Evaluation Criteria in Solid Tumors
version 1.1 (RECIST v1.1) [20]. Cases treated before the
publication of RECIST v1.1 were classified accordingly
based on data extracted from image reports. The PFS
was defined as the time from the beginning of bevacizu-
mab treatment until the first observation of disease
progression. The OS was defined as the time from the
beginning of bevacizumab treatment until the date of
either the last contact alive or death from any cause.
Hypertension was defined when blood pressure was either
persistently elevated (>24 h) or repeated blood arterial
pressure measurements were above 140 × 90 mmHg. The
Common Terminology Criteria for Adverse Events
(CTCAE) version 4.03 was used to grade hypertension
[21]. Blood pressure values recorded by physicians and
nurses during screening consultations, pre-chemotherapy,
and prior to initiation of the antihypertensive treatment
were analyzed. Archival pathological specimens were
collected, and the expression of the angiogenesis-related
proteins was first verified by immunohistochemistry and
then quantified.
Construction of tissue microarray blocks and
immunohistochemistry analysis
Archival formalin-fixed, paraffin-embedded specimens
were obtained from patients who received bevacizumab.
The chosen samples were from primary tumor and/or
metastatic tissue collected as close as possible to the start
of bevacizumab treatment. The paraffin blocks underwent
tissue microarray construction before immunostaining. In
brief, a fresh section stained with hematoxylin and eosin
was cut from each block. The representative tumor areas
were carefully selected and marked. Using a tissue micro-
arrayer (Beecher Instruments, Silver Spring, MD, USA),
1 mm cylindrical cores were removed from each donor
paraffin block and transferred to premolded recipient par-
affin blocks, in duplicates. Sections 5 μm in thickness were
placed on glass slides. In the recipient block, cores were
arrayed according to the defined x-y coordinate position.
Normal placenta tissue cores were used as a position
marker. Slides were then incubated with the primary
antibodies according to the manufacturer’s protocol.
The polyclonal antibodies used in this study were: PlGF
(1:20, R&D systems, Minneapolis, MN, USA), VEGFR2
(1:50, Neomarkers, Freemont, CA, USA), VEGFR3 (1:400,
LabVision, Freemont, CA, USA), and DLL4 (1:200,
Abcam, Cambridge, UK). The monoclonal antibodies used
were VEGFR1 (1:50, clone Y103, Abcam, Cambridge, UK)
and NOTCH1 (1:50, Thermo Scientific, clone A6, Rock-
ford, IL, USA). Antibody detection was performed using a
streptavidin-biotin system (Biotinylated Link Universal,
LSAB+, Carpinteria, CA, USA) for PlGF and a biotin-free
polymeric visualization system (Novolink Max Polymer,
Carpinteria, CA, USA) for all the other antibodies, accord-
ing to the manufacturer’s protocol. Glass slides were digi-
talized using the Aperio Scan-Scope XT Slide Scanner
(Aperio Technologies, Vista, CA, USA) at 20x magnifica-
tion. All the tumoral areas in the tissue microarray (spots)
were evaluated and scored independently by the patholo-
gist (M.M.P) and the oncologist (T.F.P.J.), without previ-
ous knowledge of the clinicopathological outcomes of the
patients. The evaluation of the immunostaining was as
follows: VEGFR1 (membrane and cytoplasm), VEGFR2
(membrane and cytoplasm), VEGFR3 (membrane and cyto-
plasm), PlGF in the cytoplasm, and DLL4 and NOTCH1 in
the membrane. A membrane staining algorithm (Mem-
brane v1, Aperio, Vista, CA, USA) was used to determine
the intensity and extent of cell membrane staining. Tumor
cells with weak or partial membrane staining were scored
1+; tumor cells with moderate and complete membrane
staining were considered 2+; tumor cells with intense
and complete membrane staining were classified as 3+.
For each TMA core, the percentage of cells with score
0, +1, +2, +3 was registered. A positive staining was
considered for cells with scores 2+ and 3+, except for
DLL4, where a score of 1+, 2+ and 3+ were considered
positive. The percentage of cells with positive staining
in each TMA core was summed up. The mean value
per replicate was used for the statistical analysis. A
sample was considered non-representative when there
were <500 analyzed cells. For the quantification of stain
in the cytoplasm, the Positive Pixel Count Algorithm
(Aperio, Vista, CA, USA) was used to sum the strongly
and moderately positive pixels in each core. The ana-
lyses included the classification of staining as strongly,
moderately and weakly positive, the number of negative
cells, the analyzed area, and the ratio of the number
of positive/total number of cells. The mean value per
replicate was used for statistical analyses. A sample
Fig. 1 Flow diagram for patient selection
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was considered non-representative when there was an
area <0.08 μm2 (10 % of the total core area).
Statistical analysis
Descriptive statistics was used for the analysis of demo-
graphic and clinical characteristics. Frequencies and per-
centages were used for nominal/ordinal variables, while
median and range were used for continuous variables. The
response rates associated with demographic and clinical
data were analyzed with the Chi-square and Fisher’s exact
tests. Logistic regression was used to test the independ-
ent effect of some variables on the objective response
rate; all variables with p ≤ 0.05 were included in associ-
ation tests. Correlations among angiogenesis-related pro-
teins employed a Pearson’s correlation test. The survival
curves were estimated using the Kaplan-Meier method
and were compared using the log-rank test. Patients who
were lost to follow-up were censored at the last contact
date. Ordinal or nominal variables were dichotomized by
grouping. To analyze the association of OS and PFS with
angiogenesis-related protein expression, patients were
subdivided into high or low-expression groups based on
the median cut-off values. The Cox multivariate regres-
sion model was used to test for independent significance
of clinical and pathological parameters on the OS.
All analyses were performed either with the R statis-
tical software, version 2.3.0 (www.r-project.org) or SPPS
v.17 statistical package (Chicago, IL, USA).
Results
Patient and tumor characteristics
Median age at diagnosis was 56 years (range, 28–80 years);
58 % of patients were male, and 51 % of patients presented
one or more comorbidities. The most common CRC
localization was descending/sigmoid colon. Although all
tumors were adenocarcinomas, 9.6 % presented mucinous
histology (mucinous and mucin-secreting) and 82.6 %
were moderately differentiated. By the time of diagnosis,
72.8 % of patients had stage IV (synchronous metastases),
the remaining patients developed metachronous metas-
tases (27.2 %), the liver being the most common site of
metastasis. Ninety-five percent of patients underwent
resection of the primary tumor, and 58 % underwent me-
tastasis resection at some point. Tumor characteristics are
presented in Table 1.
Although most of the patients had an advanced stage of
the disease at diagnosis, 96.9 % presented an ECOG
(Eastern Cooperative Oncology Group) performance sta-
tus of either 0 or 1. Bevacizumab was administered as the
first, second, third, and even the fourth line of therapy,
with the majority of cases (70 %) using it as the first-line.
Irinotecan plus 5-fluorouracil and leucovorin was the
most common chemotherapy drug regimen associated
with bevacizumab (53.3 %). Hypertension is a common
side effect of bevacizumab therapy. In our cohort,
25.8 % of patients experienced chemotherapy-related
hypertension grade 2 or 3.
Clinical outcomes
In the total cohort of 105 patients, the median PFS was
10.2 months. There was a significant association between
PFS and ECOG 0 or 1 (p = 0.002), and PFS and histo-
logical differentiation grades 1+ and 2+ (p = 0.027), shown
in Fig. 2a and b. Concerning the presence of metastasis, a
longer PFS was significantly associated with the presence
of liver metastasis (p = 0.003, Fig. 2c), absence of lymph
node metastasis (p = 0.014, Fig. 2d), absence of peritoneal
metastasis (p = 0.023, Fig. 2e), and with patients undergo-
ing metastasis resection (p < 0.001, Fig. 2f).
The median OS of the total cohort was 24.4 months
(Fig. 3a). There was a significant association between bet-
ter OS and ECOG 0 or 1 (p = 0.01, Fig. 3b). Improved OS
was also associated with histological differentiation grades
1+ or 2+ (p = 0.006, Fig. 3c), presence of liver metastasis
(p < 0.001, Fig. 3d), absence of lymph node metastasis
(p = 0.004, Fig. 3e), and with patients undergoing metas-
tasis resection (p < 0.0001, Fig. 3f). Patients who under-
went metastasis resection at some point in the course of
their disease had better OS (5-year survival rate of 40 %)
as well as better PFS, with a10-year survival rate of 18 %.
Response rates were analyzed in 95 patients since nine
patients did not present detectable disease prior to beva-
cizumab treatment and one patient had no data regard-
ing response to treatment. Association with clinical
variables is shown in Table 2. Histological differentiation
grades 1+ and 2+, non-mucinous histology, liver metas-
tasis and first-line therapy were significantly associated
with better objective response rates. In a multivariate lo-
gistic regression model for objective response the included
variables were line of bevacizumab treatment (first vs.
others), combined histology (mucin-secreting vs. non-
mucin-secreting), histological differentiation grade (1, 2
vs. 3) and the presence of liver metastasis (yes vs. no).
Bevacizumab, used in the first-line of treatment, and the
presence of liver metastasis were independently associated
with objective response rate (Table 3).
We also evaluated ORR, PFS and OS from patients that
received bevacizumab as a first-line (N = 73) and second-
line treatment (N = 29) separately. Demographics and clin-
ical characteristics of patients treated with bevacizumab as
a first-line therapy are shown in (Additional file 1: Table
S1). ORR, median PFS and median OS was 59.7 %,
10.6 months and 28.9 months in first-line and 36.0 %,
8.2 months and 19.9 months in second-line, respectively
(Additional file 1: Table S2).
Angiogenesis-related proteins were investigated by immu-
nohistochemistry in patients with the disease detected prior
to bevacizumab treatment (Additional file 2: Figure S1).
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The proteins expressed most abundantly were VEGFR1 and
NOTCH1. The expression values for VEGFRs, PlGF, DLL4
and NOTCH1 are presented in Table 4. All of the VEGF re-
ceptors 1, 2 and 3 had significant positive correlations
among each other for both membrane and cytoplasmic ex-
pression. All other significant correlations involving PlGF,
DLL4 and NOTCH1 are presented in Table 5.
The clinical characteristics significantly associated with
angiogenesis-related proteins are described in Table 6.
DLL4 did not show any significant association with clin-
ical characteristics. There was no significant association
between objective response rate and the angiogenesis-
related proteins investigated.
There was a trend toward an association between better
PFS with lower NOTCH1 expression (p = 0.06, Fig. 4a).
Better OS was significantly associated with lower NOTCH1
expression (p = 0.01, Fig. 4b). To determine the variables
independently associated with OS, ECOG (0, 1 vs. 2, 3),
metastasis resection (yes vs. no), lymph node metastasis
(yes vs. no), peritoneal metastasis (yes vs. no), liver metas-
tasis (yes vs. no), histological grade (1, 2 vs. 3), and
NOTCH1 expression (lower vs. higher) were included in a
multivariate analysis shown in Table 7.
Discussion
This retrospective analysis reports on the efficacy of
bevacizumab administered across multiple lines of treat-
ment in a large cohort of patients from a reference center
in Brazil. We report the expression profile of angiogenesis-
related proteins and their association with clinical charac-
teristics and outcomes.
Several phase III clinical trials have confirmed the effi-
cacy of bevacizumab in combination with FOLFOX or
FOLFIRI in the first-line treatment for metastatic CRC
[10, 22]. In 100 patients receiving, as the first-line therapy,
bevacizumab with irinotecan, 5-fluorouracil and leucov-
orin, a median PFS of 8.8 months was reported compared
to 6.8 months in the group without bevacizumab [10].
Table 1 Tumor characteristics
Characteristics Frequency
Localization (n = 104)
Descending/sigmoid colon 57.7 %
Medium and lower rectum 22.1 %
Ascending colon 17.3 %
Transverse colon 2.9 %
Histology (n = 104)
Adenocarcinoma NOS 50.0 %
Tubular adenocarcinoma 39.4 %
Mucin-secreting adenocarcinoma 4.8 %
Mucinous adenocarcinoma 3.8 %
Signet ring cell carcinoma 1.0 %
Cribriform adenocarcinoma 1.0 %
Histologic differentiation (n = 92)
Well (1) 6.5 %
Moderate (2) 82.6 %
Poor (3) 10.9 %
Blood vessel invasion (n = 81)
Yes 16.0 %
No 84 %
Lymphatic invasion (n = 80)
Yes 36.3 %
No 63.7 %
Perineural invasion (n = 78)
Yes 30.8 %
No 60.2 %











Metastasis (M1) at diagnosis (n =104)
Yes 72.8 %
No 27.2 %





Table 1 Tumor characteristics (Continued)
Metastatic sites (n = 105)
Liver 65.7 %




Locoregional recidive 11.5 %
Metastasis resection (n = 105)
Yes 58.1 %
No 41.9 %
n: number of patients with available data in each category. Tumors were
staged according to the 7th Edition of the TNM Classification of Malignant
Tumors. NOS: not otherwise specified
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Reported PFS in this setting varied from 7 to 11 months
[11, 22, 23]. In our cohort of 105 patients, 70.0 % received
bevacizumab in the first-line treatment with the median
PFS of 10.6 months. Although this cohort included a high
proportion of patients with advanced disease, our results
are in line with reported data confirming the clinical value
of bevacizumab. As to be expected, a significantly better
PFS was associated with ECOG 0 or 1 and histological dif-
ferentiation grades 1+ and 2+. Additionally, a better PFS
was significantly associated with the absence of extrahe-
patic metastasis and the presence of liver metastasis, an
outcome probably related to the high rate of metastasis re-
section (58.1 %). Our data showed a median OS of
24.4 months, in line with the literature and associated with
Fig. 2 The progression-free survival curves according to: ECOG (1 = ECOG 0, 1 vs. 2 = ECOG 2, 3), p = 0.002 (a); histogical grade (well differentiated =
grade 1, moderately differentiated = grade 2 vs. poorly differentiated = grade 3), p = 0.0027 (b); with liver metastasis (yes vs. no), p = 0.003 (c); lymph
node metastasis (yes vs. no), p = 0.014 (d); peritoneal metastasis (yes vs. no), p = 0.023 (e), and patients who underwent metastasis resection
(yes vs. no), p < 0.001 (f). The survival curves were calculated using the Kaplan-Meier method, and the log-rank test was used for comparison.
ECOG: Eastern Cooperative Oncology Group performance status score
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similar factors that were also related to a better PFS, such
as liver metastasis and metastasis resection [12, 22, 24, 25].
Concerning objective responses, better response rates were
seen in histological differentiation grades 1+ and 2+,
non-mucinous histology, liver metastasis, and bevacizu-
mab as the first-line therapy. However, only the last two
variables were independently associated. Importantly, the
objective response rate was 59 % in patients who used
bevacizumab as the first-line therapy (67 patients in this
analysis).
We analyzed the occurrence of hypertension, the most
common side effect of bevacizumab. Hypertension ap-
pears to be dose-dependent, and it is currently under an
investigation as a biomarker for VEGF inhibition efficacy
[26, 27]. Bevacizumab-induced hypertension has been re-
ported to be highly associated with improvements in PFS,
Fig. 3 The overall survival curves from the start of bevacizumab treatment. Overall survival curve from the total cohort (n= 105 patients), median of
24.4 months (a). Overall survival curves according to: ECOG (1 = ECOG 0, 1 vs. 2 = ECOG 2, 3), p = 0.001 (b); histogical grade (well differentiated = grade 1,
moderately differentiated = grade 2 vs. poorly differentiated = grade 3), p= 0.006 (c); liver metastasis (yes vs. no), p< 0.001 (d); lymph node metastasis
(yes vs. no), p = 0.004 (e), and patients who underwent metastasis resection (yes vs. no), p< 0.001 (f). The survival curves were calculated using the
Kaplan-Meier method, and the log-rank test was used for comparison. ECOG: Eastern Cooperative Oncology Group performance status score
Paiva et al. BMC Cancer  (2015) 15:643 Page 7 of 12
OS, and the overall RR [27]. In our study, hypertension
grades 2 and 3 were present in 25.8 % of patients. Grade 3
hypertension was present in 13.9 %, in line with previously
reported data [28]. However, we did not identify a signifi-
cant association between the presence of hypertension
and objective response rate. No significant association was
seen between outcomes or expression of angiogenesis-
related proteins and hypertension.
Although outcome results may vary, the use of bevaci-
zumab therapy has been well established [25, 29]. How-
ever, the heterogeneity of results shown in several clinical
trials demonstrates an urgent need for biomarkers predict-
ing bevacizumab treatment outcome and toxicity. Different
biomarkers such as mutations of BRAF and KRAS [30],
microvessel density and VEGF levels [31] have been stud-
ied, but no predictive factors have been identified. Bio-
markers would allow for the selection of patients most
prone to respond to antiangiogenic therapy. In this cohort,
the most expressed angiogenesis-related proteins were
VEGFR1 and NOTCH1 with a median value of ~ 65 %
positive cells.
PlGF is a VEGF homolog and a ligand for VEGFR1
that acts by amplifying the responsiveness of VEGFR1
to VEGF during pathological angiogenesis [32].
NOTCH1 signaling activation has been shown to in-
duce VEGFR1 expression [33] and enhance its respon-
siveness to PlGF [34]. In line with this, we found significant
positive correlations between the expression of VEGFR1
(membrane and cytoplasm) and PlGF, as well as between
VEGFR1 (membrane and cytoplasm) and NOTCH1, and
NOTCH1 and PlGF. However, although there is a negative
NOTCH1 signaling feedback to VEGFR2, resulting in
Table 2 Association between clinical variables and objective
response by RECIST





Grade 1 + 2 74 42 (57) 32 (43) 0.01
3 9 1 (11) 8 (89)
Mucinous histology no 84 46 (55) 38 (45) 0.048
yes 10 2 (20) 8 (80)
Liver metastasis no 31 8 (26) 23 (74) 0.001
yes 64 40 (62) 24 (38)
Peritoneal metastasis no 79 43 (54) 36 (46) 0.09
yes 16 5 (31) 11 (69)
Chemotherapy FOLFIRI 52 25 (48) 27 (52) 0.43
FOLFOX 39 22 (56) 17 (44)
Hypertension no 61 29 (47) 32 (53) 0.41
yes 30 17 (57) 13 (43)
Chemo + bevacizumab as
first-line therapya
no 28 9 (36) 19 (64) 0.02
yes 67 40 (60) 27 (40)
RECIST: Response Evaluation Criteria in Solid Tumors; FOLFIRI: infusional
5-fluoro-uracyl plus leucovorin plus irinotecan; FOLFOX: infusional 5-fluoro-uracyl
plus leucovorin plus oxaliplatin; CR: Complete Response; PR: Partial Response;
SD: Stable Disease; PD: Progressive Disease (PD). Data are number of patients and
numbers in parentheses are percentages. aChemo: chemotherapy
Table 3 Multivariate logistic regression analysis showing the
variables independently associated with objective response rate
(n = 83 patients)
Covariates Odds ratio CI 95 % p value
Chemo + bevacizumaba
First-line vs. others 3.65 1.03–12.87 0.032
Liver metastasis
yes vs. no 4.12 1.18–14.29 0.027
Histological grade




0.47 0.03 – 6.18 0.56
CI: Confidence interval. aChemo: chemotherapy








Membrane 96 64.5 1 – 76
Cytoplasm 96 60.4 0 - 86.7
VEGFR2
Membrane 96 9.5 0 – 64
Cytoplasm 92 22 0.35 – 72.8
VEGFR3
Membrane 96 17 0 – 67
Cytoplasm 94 26.3 2.06 – 80.1
PlGF 93 38.9 0.44 – 83.1
DLL4 92 27 1 – 99
NOTCH1 96 69 6 – 79
Table 5 Correlations between angiogenesis-related proteins
Angiogenesis-related proteins Correlation coefficient p
PlGF and membrane VEGFR1 0.50 <0.0001
PlGF and cytoplasm VEGFR1 0.58 <0.0001
PlGF and cytoplasm VEGFR2 0.23 <0.0001
DLL4 and membrane VEGFR1 0.28 0.0243
DLL4 and cytoplasm VEGFR1 0.28 0.0056
DLL4 and PLGF 0.24 0.0172
DLL4 and NOTCH1 0.25 0.0161
NOTCH1 and membrane VEGFR1 0.56 <0.0001
NOTCH1 and cytoplasm VEGFR1 0.34 <0.0001
NOTCH1 and PlGF 0.27 0.0072
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decreased endothelial cell proliferation in response to
VEGF [35], there was no significant correlation between
the expression of NOTCH1 or DLL4 and VEGFR2. While
bevacizumab treatment has been associated with increased
levels of PlGF [36], its value as a biomarker remains largely
unknown. Instead of contributing to tumor escape and re-
sistance, as has been suggested, increased PlGF expression
might only be a host response elicited by angiogenic ther-
apies [37] since it has been associated with better out-
comes in glioblastoma [38].
We also analyzed the association of angiogenesis-related
protein expressions with clinical and pathological character-
istics. In tumors or plasma, VEGFR1 is a strong biomarker
candidate to predict response to bevacizumab [39]. The
median expression of VEGFR1 was twice that of VEGFR2
in our cohort, and higher expression of membrane VEGFR1
was associated with lung metastasis. In the MAX III trial
(testing the combination of capecitabine, bevacizumab and
mitomycin), the authors observed an association between
low VEGFR1 expression by immunohistochemistry on tu-
mors and improved OS [39].
VEGFR3 is a major inducer of lymphangiogenic signaling,
but its expression has been associated with the presence of
hematogenous metastasis [40] and poor OS [41]. In our co-
hort, while higher expression of membrane and cytoplasmic
VEGFR3 was associated with lung metastasis, lower expres-
sion was associated with liver metastasis. YILDIZ et al.
(2010) evaluated the expression of VEGFR3 by immunohis-
tochemistry in tumor samples from metastatic colorectal
cancer patients treated with chemotherapy and bevacizu-
mab and observed positive expression in 20 % of cases. The
authors did not identify any association with efficacy out-
comes [42].
Increased NOTCH1 expression was associated with
lymph node metastasis, which is in line with previously
reported data [43, 44].
PFS was not significantly associated with any of the
angiogenesis-related proteins. We saw a trend toward
Table 6 Association between expression of angiogenesis-
related proteins and clinical characteristics
Characteristic p
VEGFR1
Membrane Lung metastasis 0.002
Cytoplasm Stage I and II 0.03
VEGFR2
Cytoplasm Stage I and II 0.03
VEGFR3
Membrane Lung metastasis 0.001
Liver metastasis 0.03
Cytoplasm Lung metastasis 0.003
PlGF Stages I and II 0.04
NOTCH1 Metastasis to regional lymph nodes (N1 or N2) 0.04
Fig. 4 The progression-free survival curve for NOTCH1 expression, p = 0.06 (a), and the overall survival for NOTCH1, p = 0.01 (b). Low
expression: < median expression value vs. high expression: ≥ median expression value. The survival curves were calculated using the
Kaplan-Meier method, and the log-rank test was used for comparison
Table 7 Multivariate regression analysis for overall survival (OS).
Eighty-eight patients with complete data were included in this
analysis
Covariates HR CI 95 % p
Liver metastasis (yes vs. no) 1.93 1.09 – 3.44 0.024
Histological grade (1 + 2 vs. 3) 2.79 1.16 – 6.68 0.021
ECOG (0 + 1 vs. 2 + 3) 20.50 3.08 – 136.11 0.002
NOTCH1 2.01 1.07 – 3.77 0.029
HR: Hazard ratio; ECOG: Eastern Cooperative Oncology Group performance
status score; CI: Confidence interval
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longer PFS in patients whose tumors bore lower ex-
pression of NOTCH1, most likely because NOTCH1
expression might be involved in tumor resistance to
bevacizumab. Angiogenesis induced by DLL4-NOTCH1
signaling generates large vessels that increase tumor
blood supply and diminish sensitivity to bevacizumab
[16]. Besides, lower expression of NOTCH1 was signifi-
cantly associated with better OS. NOTCH1 activation
induces VEGFR3 [5], and it has already been associated
with poor survival [43]. In multivariate analysis, the
only factors that were independently associated with
PFS were histological grade and metastasis resection.
For OS, NOTCH1 remained an independent variable,
confirming the reported association between overactivated
NOTCH signaling and poor survival in CRC [43]. CHU et
al. described that, among 1003 tumor samples from early
stage resected colorectal cancer, 52.1 % of cases were posi-
tive for NOTCH1 and 33.4 % for NOTCH2 by immuno-
histochemistry. Patients bearing NOTCH1 positive
tumors had worse OS (38 months vs 66 months for
NOTCH1 negative cases). The opposite results were ob-
served in association with NOTCH2 expression, where
low NOTCH2 was associated with worse OS [45]. Simi-
larly, we also found that NOTCH1 hyperexpression is as-
sociated with reduced OS, however differently from the
studies by CHU et al. (2011) [46, 47], our cohort is com-
posed solely of metastatic colorectal cancer patients
treated with chemotherapy plus bevacizumab. Although,
we can not draw conclusions on the predictive capacity of
NOTCH1, we believe it is definitely prognostic, and, to
our knowledge, this is the first published report showing
this association in this population.
In summary, the results of this retrospective study are
similar to the outcomes observed in large clinical trials
confirming the effectiveness of bevacizumab in common
daily practice. The expression profile of angiogenesis-
related proteins and their association with clinicopatho-
logical characteristics and outcomes were described,
building on the current understanding of the role of these
proteins in the setting of chemotherapy in addition to bev-
acizumab therapy. Our results suggest that NOTCH1
might serve as a prognostic marker for colorectal cancer
in the metastatic setting.
Conclusion
We evaluated the expression of proteins involved with
angiogenesis in colorectal tumor samples from patients
receiving bevacizumab in conjunction with chemother-
apy. High expression levels of VEGFR1 and VEGFR3
were associated with a higher rate of lung metastasis.
VEGFR3 expression was also associated with liver me-
tastasis. NOTCH1 expression was associated with an
increased risk of lymph node metastasis and a worse
overall survival.
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